Which of the following is NOT known to prolong the QT interval and carry a risk of torsades de pointes?

Sotalol

Ibutilide

Procainamide

Lidocaine

The key idea is how drugs affect the heart’s repolarization and the risk of torsades de pointes. Drugs that block potassium channels and delay repolarization tend to lengthen the QT interval and can trigger torsades de pointes, especially with electrolyte disturbances or other QT-prolonging drugs.

Sotalol and ibutilide are both class III antiarrhythmics that markedly slow repolarization by blocking potassium channels, so they reliably prolong the QT interval and carry a risk of torsades de pointes. Procainamide, a class IA drug, also lengthens the QT by delaying repolarization, so it can contribute to torsades, though its risk profile differs and is generally linked to its QT prolongation effect.

Lidocaine, on the other hand, is a class IB sodium channel blocker. It primarily acts on depolarized/ischemic tissue and has little to no effect on the overall QT interval; it does not prolong repolarization and is not associated with torsades de pointes.

Want more questions?

All options are one-time payments.

$25.99

30 day pass for new members

All the basics to get you started

  • Ad-free experience
  • View your previous attempt history
  • Mobile app access
  • In-depth explanations
  • 30 day premium pass access
$59.99$171.99 usd

6 month DELUXE pass (most popular)

Full access FOR 6 MONTHS! & the ultimate digital PDF study guide (BONUS)

  • $171.99 usd value for $59.99! You save $106!
  • Ad-free experience
  • View your previous attempt history
  • Mobile app access
  • In-depth explanations
  • 6 months of full access
  • Ultimate digital PDF study guide included
  • Priority support
$15.99 $24.99

Ultimate digital PDF study guide

For those that prefer a more traditional form of learning

  • Available for instant download
  • Available offline
  • Hundreds of practice multiple choice questions
  • Comprehensive content
  • Detailed explanations
Image Description
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy